A trial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in HemoDialysis Patients: A Safety Device Study
- "no reduction in serum albumin;
reduction in pre-dialysis lambda- and kappa-FLC vs baseline;
no improvement in restless legs symptoms, quality of life, 6MWT or MIS scores"